These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Pressing Issues in COVID-19: Probable Cause to Seize SARS-CoV-2 for Its Preferential Involvement of Posterior Circulation Manifesting as Severe Posterior Reversible Encephalopathy Syndrome and Posterior Strokes. D'Amore F; Vinacci G; Agosti E; Cariddi LP; Terrana AV; Vizzari FA; Mauri M; Giorgianni A AJNR Am J Neuroradiol; 2020 Oct; 41(10):1800-1803. PubMed ID: 32732268 [TBL] [Abstract][Full Text] [Related]
6. Hemorrhagic Posterior Reversible Encephalopathy Syndrome as a Manifestation of COVID-19 Infection. Franceschi AM; Ahmed O; Giliberto L; Castillo M AJNR Am J Neuroradiol; 2020 Jul; 41(7):1173-1176. PubMed ID: 32439646 [TBL] [Abstract][Full Text] [Related]
8. Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome. Odièvre MH; de Marcellus C; Ducou Le Pointe H; Allali S; Romain AS; Youn J; Taytard J; Nathan N; Corvol H Am J Hematol; 2020 Aug; 95(8):E192-E194. PubMed ID: 32358817 [No Abstract] [Full Text] [Related]
9. Transient cortical blindness in COVID-19 pneumonia; a PRES-like syndrome: Case report. Kaya Y; Kara S; Akinci C; Kocaman AS J Neurol Sci; 2020 Jun; 413():116858. PubMed ID: 32387762 [No Abstract] [Full Text] [Related]
10. Posterior reversible encephalopathy syndrome - A pathology that should not be overlooked in the era of COVID-19. Ioan P; Ribigan AC; Rusu O; Bratu IF; Badea RS; Antochi F Am J Emerg Med; 2022 Jun; 56():393.e5-393.e8. PubMed ID: 35346531 [TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient. Allam SR; Dao A; Madhrira MM; Antiporta PB; Nair RR; Guiteau JJ; Reyad AI Transpl Infect Dis; 2020 Aug; 22(4):e13326. PubMed ID: 32406985 [No Abstract] [Full Text] [Related]
12. Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19. Gade AR; Alavala H; Allam SR Kidney Int; 2020 Oct; 98(4):1054. PubMed ID: 32650019 [No Abstract] [Full Text] [Related]
16. The complement inhibitors in COVID-19: future expectations. Korotchaeva Y; Kozlovskaya N; Bobrova L; Kamyshova E; Demyanova K; Moiseev S Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):6480-6481. PubMed ID: 32633332 [No Abstract] [Full Text] [Related]
17. [Neurological Manifestations of COVID-19: Meningoencephalitis and Encephalopathy]. Nakajima H Brain Nerve; 2020 Oct; 72(10):1031-1037. PubMed ID: 33051388 [TBL] [Abstract][Full Text] [Related]
18. Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma. Chaidos A; Katsarou A; Mustafa C; Milojkovic D; Karadimitris A Br J Haematol; 2020 Jul; 190(1):e9-e11. PubMed ID: 32369612 [No Abstract] [Full Text] [Related]
19. Neurological emergencies associated with COVID-19: stroke and beyond. Agarwal A; Pinho M; Raj K; Yu FF; Bathla G; Achilleos M; ONeill T; Still M; Maldjian J Emerg Radiol; 2020 Dec; 27(6):747-754. PubMed ID: 32778985 [TBL] [Abstract][Full Text] [Related]
20. Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19. Faguer S; Del Bello A; Abravanel F; Nicolau-Travers ML; Kamar N Ann Intern Med; 2020 Sep; 173(6):501-503. PubMed ID: 32432518 [No Abstract] [Full Text] [Related] [Next] [New Search]